(A Top Pick Jul 12/22, Down 2.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with LEVI is progressing well. We now recommend to trail up the stop from $13 to $15.
(A Top Pick Jul 12/22, Down 11.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with LEVI has triggered its stop at $15. To remain disciplined, we recommend covering the position at this time.
Today, it reported an earnings and sales beat, but shares fell 16%. They lowered their full-year gross margin outlook a lot, but didn't touch earnings guidance. Also, they forecast a sales decline around 8-12% this quarter.
Could benefit from the weight-loss drug boom, because those who take those drugs will need need jeans. But the company reported a weak quarter and cut guidance.
They just reported a minor sales miss but an earnings beat and cut their full-year revenue forecast though asserted their earnings would meet the midpoint of previous guidance. Europe and direct-to-consumer are strong, but Asian and America are weaker.
It reported after the bell superb 12% YOY sales growth, strength in the Americas, Europe and direct to consumer channels. They beat gross margins, but due to higher expenses, they delivered a modest earnings beat. Their full-year forecast was a little mixed, but overall good.
They delivered a solid quarter, sales strong with an earnings beat thanks to higher than expected margins. Guidance is unchanged. Shares are down 45% from highs last June, but showed life at today's close.
Your Watchlist
Add stocks to watchlist to monitor them daily and get important alerts.